A recent Delhi High Court ruling in a trademark dispute between Novo Nordisk and Dr. Reddy's Laboratories shows India's approach to intellectual property law when balanced against public health needs for essential medications like diabetes drugs.
Court Order: 30 Days to Sell Diabetes Drugs
The court's March 30, 2026, decision walked a careful line, upholding Novo Nordisk's 'Ozempic' trademark while ensuring the continued availability of semaglutide, a vital drug for type 2 diabetes. Justice Jyoti Singh allowed Dr. Reddy's Laboratories to sell its existing stock of semaglutide injections, branded 'OLYMVIQ', for another 30 days. Any unsold inventory must then be donated to a government hospital. The ruling explicitly prioritized public interest, calling it more beneficial than ordering the drugs destroyed. The court noted the phonetic similarity between 'OLYMVIQ' and 'Ozempic' could confuse consumers and had previously ordered Dr. Reddy's to stop sales and marketing of the infringing brand. However, the drug's critical nature and prescription-only status, with no quality issues raised, heavily influenced the final decision.
Dr. Reddy's had already agreed to switch to a new brand, 'Olymra', and stop using 'OLYMVIQ', a move Novo Nordisk accepted. The main issue became the fate of the existing inventory, with Dr. Reddy's citing the drug's temperature sensitivity as a factor against immediate destruction or relabeling.
India's Balance of IP and Public Health
This ruling fits India's established position of balancing strong intellectual property protection with the need for affordable medicine access, earning it the nickname 'pharmacy of the Global South'. Indian patent law, guided by the TRIPS agreement, has rules like Section 3(d) to prevent patent evergreening and allows compulsory licensing in certain cases, showing its commitment to public health.
Market Growth and Company Positions
The global market for semaglutide is growing rapidly due to rising rates of type 2 diabetes and obesity, with projections to reach over $93 billion by 2035. Ozempic is a major player, holding a significant market share. Novo Nordisk, a global leader in diabetes and obesity care, has seen significant revenue growth from Ozempic and Wegovy. Its P/E ratio is around 10.3, reflecting its market valuation. The company's stock trades near $36.98. However, analyst sentiment is mixed, with many rating it a 'Hold'.
Dr. Reddy's Laboratories, a major Indian pharmaceutical firm, has a market capitalization of about $11.41 billion and a P/E ratio near 18.3. Its stock trades around ₹1,217.30. The Indian diabetes drug market is projected to reach over $2.16 billion by 2031, presenting a significant domestic opportunity. Recently, Novo Nordisk was forced to cut prices for Ozempic and Wegovy in India by up to 48% to compete with cheaper generics from Indian manufacturers like Dr. Reddy's, Sun Pharma, and Zydus. This followed the expiry of its semaglutide patent in March 2026. This competitive pressure highlights the importance of market access and affordability in India.
Challenges for Both Companies
While Dr. Reddy's gained relief on existing stock, transitioning to 'Olymra' means costs for rebranding, inventory, and marketing adjustments. Furthermore, the court finding trademark infringement, even with a lenient stock outcome, sets a precedent that could lead to future legal challenges or increased scrutiny. Dr. Reddy's P/E ratio of 18.3 is higher than Novo Nordisk's 10.3, suggesting a potentially higher valuation relative to earnings.
For Novo Nordisk, the ruling, while affirming its trademark, also shows the challenges of maintaining exclusivity in a market prioritizing public health access. Recent price cuts in India and more generic competitors mean Novo Nordisk faces significant margin pressure and market share loss in the region. Its stock ratings have shifted toward 'Hold', and aggressive pricing in India suggests a defensive strategy against generics. The recent acquisition of three manufacturing sites from Catalent has also impacted its free cash flow, according to its 2024 annual report.
Future Outlook for Diabetes Drugs
The Delhi High Court's decision reinforces India's legal framework balancing patent holder rights with the fundamental need for accessible healthcare. This approach could serve as a template for other jurisdictions facing similar issues in the pharmaceutical sector, especially as blockbuster drugs near patent expiry. The intense competition in India's semaglutide market, driven by generics and price cuts, means companies must strategically navigate IP rights and market access to stay profitable.